Abbott Laboratories Q3 2025 Earnings Recap

ABT Q3 2025 October 16, 2025

Get alerts when ABT reports next quarter

Abbott Laboratories reported a robust 7.5% organic sales growth in Q3 2025, primarily driven by a strong performance in medical devices and established pharmaceuticals, despite a decline in COVID test sales.

Earnings Per Share Beat

$1.30 vs $1.30 est.

+0.0% surprise

Revenue Miss

11369000000 vs 11389704247 est.

-0.2% surprise

Market Reaction

1-Day +0.71%

5-Day -1.01%

30-Day +1.88%

See ABT alongside your other holdings

Add to your portfolio — free

Key Takeaways

Earnings per share rose to $1.30, reflecting high single-digit growth year-over-year, excluding COVID test impacts.
New product launches contributed nearly $5 billion in sales this quarter, adding over 100 basis points to organic sales growth.
Medical Devices segment grew by 12.5%, led by solid performances in diabetes care and electrophysiology.
Established Pharmaceuticals experienced high single-digit growth, driven by strong contributions from core markets and therapeutic areas.
Strategic investments in nutrition products are set to leverage favorable consumer trends, evidenced by new launches in the adult nutrition segment.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit ABT on AllInvestView.

Next Q1 2026